| Literature DB >> 2650662 |
E Mohr1, J Schlegel, G Fabbrini, J Williams, M M Mouradian, U M Mann, J J Claus, P Fedio, T N Chase.
Abstract
A loss of cortical noradrenergic innervation may contribute to the intellectual deterioration in Alzheimer's disease. To test the hypothesis that noradrenergic replacement may confer symptomatic benefit, a double-blind, placebo-controlled therapeutic trial with clonidine hydrochloride (Catapres), a centrally active noradrenergic receptor agonist, was undertaken in eight patients with the clinical diagnosis of Alzheimer's disease. No statistically significant changes in cognitive function were found over a range of doses, including those that produced clinically observable side effects. These preliminary results indicate a need for alternative noradrenergic replacement strategies in Alzheimer's disease.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2650662 DOI： 10.1001/archneur.1989.00520400030015
Source DB: PubMed Journal: Arch Neurol ISSN： 0003-9942